Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
The binding properties of activated C3 to immune complexes were studied by using solubilization phenomenon as a model system. IgG or F(ab')2 immune precipitates were solubilized by the six isolated alternative pathway proteins, and the solubilized complexes were analyzed by SDS-PAGE. As a result of solubilization, we observed some high m.w. bands. Under reducing conditions, the bands with m.w. of 150,000 and 115,000 appeared in the case of IgG and F(ab')2 complexes, respectively. Two-dimensional SDS-PAGE revealed that hydroxylamine treatment resulted in the dissociation of the 150,000-m.w. polypeptide into the C3 alpha-65 and the heavy chain of IgG. Similarly, the 115,000-m.w. polypeptide was dissociated into the C3 alpha-65 and the Fd chain. Therefore, it is likely that iC3b binds covalently to the Fd region of the heavy chain of IgG via an ester bond. Under nonreducing conditions, iC3b-IgG and iC3b-F(ab')2 complexes had apparent m.w. of 340,000 and 270,000, respectively, corresponding to one iC3b molecule bound to one antibody molecule. In addition, a considerable amount of iC3b also binds to antigen molecules via an ester bond. The findings that C3 binds to the F(ab')2 molecules and bovine serum albumin, which contain only a small amount of carbohydrate, suggest that C3 may not bind to the carbohydrate moiety of antibody molecules. Indeed, various carbohydrate molecules did not inhibit the solubilization even at high concentrations. In contrast, acetyl tyrosine having an aromatic ring and a hydroxyl group produced the best inhibition of the solubilization. Furthermore, we demonstrated that generation of C3b in the presence of 3H-tyrosine resulted in covalent binding of the tyrosine specifically to the C3 alpha' chain, indicating that the inhibition of solubilization may be due to the competition between tyrosine and immune complexes for the covalent binding of C3. Thus, it could be concluded that C3 binds covalently to the amino acid residues of antigen and antibody molecules during solubilization.
D000588:Amines / Q000494:pharmacology; D000596:Amino Acids / Q000494:pharmacology; D000818:Animals; D000936:Antigen-Antibody Complex / Q000032:analysis / Q000378:metabolism*; D000937:Antigen-Antibody Reactions; D001667:Binding, Competitive; D002241:Carbohydrates / Q000494:pharmacology; D011232:Chemical Precipitation; D003167:Complement Activation; D003176:Complement C3 / Q000276:immunology / Q000378:metabolism*; D003170:Complement Pathway, Alternative; D004347:Drug Interactions; D004591:Electrophoresis, Polyacrylamide Gel; D006168:Guinea Pigs; D006801:Humans; D007700:Kinetics; D008970:Molecular Weight; D010047:Ovalbumin / Q000378:metabolism; D011817:Rabbits; D011951:Receptors, Complement / Q000032:analysis; D017463:Receptors, Complement 3b; D012995:Solubility
D000588:Amines; D000596:Amino Acids; D000936:Antigen-Antibody Complex; D002241:Carbohydrates; D003176:Complement C3; D011951:Receptors, Complement; D017463:Receptors, Complement 3b; D010047:Ovalbumin